Recent News

• 08.14.2025 - BrainStorm Cell Therapeutics Announces Second Quarter 2025 Financial Results and Provides Corporate Update
• 08.08.2025 - BrainStorm to Announce Second Quarter Financial Results and Provide a Corporate Update
• 07.17.2025 - BrainStorm Cell Therapeutics Announces Nasdaq Delisting and Transition to OTCQB
• 07.08.2025 - FDA Review of Citizen Petition Offers a Fresh Look at NurOwn®'s Evidence of Treatment Effectiveness
• 06.16.2025 - BrainStorm Announces New Survival Data from Expanded Access Program Cohort: Remarkably 90% of ALS Patients Survived Over 5 Years with NurOwn®
• 05.27.2025 - BrainStorm Secures Key Manufacturing Partnership with Minaris for Upcoming NurOwn® Phase 3b ALS Clinical Trials
• 05.19.2025 - BrainStorm Receives FDA Clearance to Initiate Phase 3b Trial of NurOwn® for ALS

Recent Filings

• 07.22.2025 - RW Registration Withdrawal Request
• 07.17.2025 - EX-99.1 EX-99.1
• 07.17.2025 - 8-K Current report
• 07.03.2025 - S-8 Securities to be offered to employees in employee benefit plans
• 06.25.2025 - 8-K Current report
• 06.25.2025 - S-3 Registration statement under Securities Act of 1933
• 06.16.2025 - 8-K Current report
• 06.16.2025 - EX-99.1 EX-99.1
• 05.19.2025 - EX-99.1 EX-99.1
• 05.19.2025 - 8-K Current report